Trump's drug pricing EO includes wins on pill penalty reform, faster approvals, and PBM rules, but adds scrutiny on pricing ...

Port Therapeutics and other early biotech startups face funding challenges as investors prefer clinical-stage companies, with ...

A rival bid by Ayrmid for bluebird bio hasn't crossed the finish line, the biotech said, after failing to confirm financing ...

Trump's pharma tariffs prompt companies to assess vulnerabilities. J&J expects $400M in costs. Immunocore's Kimmtrak, Acadia's Nuplazid & Daybue may face impact. Companies highlight US manufacturing ...

Glycomine raises $115M Series C to advance GLM101, a mannose-1-phosphate therapy for PMM2-CDG rare disease, toward Phase 2b ...

Trump signs EO on drug pricing, supports PhRMA reforms for Medicare negotiations timeline, calls for Canadian drug imports, ...

GeneDx will pay up to $33 million in cash upon the deal's expected closing this quarter. GeneDx could spend up to $51 million ...

Sanofi's amlitelimab fails Phase 2 asthma trial at highest dose, but company sees path forward based on medium dose results in specific patient subgroup ...

Merck licenses Cyprumed's oral drug delivery platform in $493M deal to develop oral peptide formulations, potentially for GLP-1 drugs.

In a sign of life for the digital therapeutics industry, Click Therapeutics has received FDA clearance with its treatment for ...

The Johnson & Johnson CEO subtly but assertively criticized the Trump administration’s plans for pharmaceutical tariffs, ...

European regulators on Tuesday authorized the use of Biogen and Eisai’s Alzheimer’s treatment Leqembi for some early-stage ...